Sarepta Therapeutics (SRPT) Cash & Current Investments (2010 - 2026)

Sarepta Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $685.0 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 31.04% year-over-year to $685.0 million; the TTM figure through Mar 2026 stood at $685.0 million (up 31.04% YoY), while the FY2025 annual figure was $853.0 million, down 37.04% from the prior year.
• Cash & Current Investments was $685.0 million for Q1 2026 at Sarepta Therapeutics, down from $853.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.1 billion in Q3 2022 to a low of $522.8 million in Q1 2025.
• Historically, Cash & Current Investments has averaged $1.4 billion across 5 years, with a median of $1.5 billion in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments plunged 62.41% in 2025, then jumped 31.04% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $2.0 billion in 2022, then dropped by 15.74% to $1.7 billion in 2023, then retreated by 19.18% to $1.4 billion in 2024, then tumbled by 37.04% to $853.0 million in 2025, then dropped by 19.69% to $685.0 million in 2026.
• The last three Cash & Current Investments figures came in at $685.0 million (Q1 2026), $853.0 million (Q4 2025), and $642.5 million (Q3 2025), per Business Quant data.